Abstract B6: Folylpoly-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in non-small cell lung cancer (NSCLC)
Background: The antifolate pemetrexed targets multiple enzymes involved in pyrimidine and purine synthesis including thymidylate synthase (TS). After entry into cells, pemetrexed is converted to polyglutamated forms by folylpoly-γ-glutamate synthetase (FPGS), a critical step to achieve full target i...
Saved in:
Published in | Clinical cancer research Vol. 18; no. 3_Supplement; p. B6 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.02.2012
|
Online Access | Get full text |
Cover
Loading…
Abstract | Background: The antifolate pemetrexed targets multiple enzymes involved in pyrimidine and purine synthesis including thymidylate synthase (TS). After entry into cells, pemetrexed is converted to polyglutamated forms by folylpoly-γ-glutamate synthetase (FPGS), a critical step to achieve full target inhibition. We hypothesized that FPGS and TS protein expression may predict outcome following pemetrexed-treatment of patients with advanced NSCLC, like in malignant pleural mesotheliomas (Christoph et al., J Clin Oncol. 2011: 29 suppl.). This is the largest report on pemetrexed-treatment outcome based on TS and FPGS in Caucasian patients with advanced NSCLC.
Methods: Pretreatment tumor samples from 161 patients (pts) with metastatic NSCLC, treated with pemetrexed combined with platinum (74 pts (46%)) or as single agent (82 pts (51%)) or within other combinations (5 pts (3%)), were retrospectively analyzed. FPGS and TS protein expression levels were evaluated by IHC using the H-Scoring system (0–300), which relies on the product of intensity (range 0 to 3) and the percentage of positive tumor cells (0–100%). Radiographic evaluation of response was performed according to RECIST criteria (version 1.1).
Results: Median pretreatment H-scores were 180 for FPGS (range: 0–280) and 205 (range: 120–290) for TS. Using the log-rank test and the median H-score as cut-off, we found a significant association between low TS protein expression and improved progression-free survival (PFS) (median PFS of 5.5 months vs. 3.4 months; hazard ratio [HR] 0.66, 95% CI, 0.45 to 0.96; P=0.03) or prolonged overall survival (median OS of 33.9 months vs. 15.0 months; hazard ratio [HR] 0.52, 95% CI, 0.31 to 0.86; P=0.01). Moreover, high FPGS protein expression was only associated with better PFS (median PFS of 5.5 months vs. 3.4 months; hazard ratio [HR] 0.58, 95% CI, 0.37 to 0.89; P=0.03). Considering exclusively patients suffering from adenocarcinomas (110 pts (68%)), TS was associated with objective response to pemetrexed-based treatment (mean H-score 192 for responders vs. 210 for non-responders, P=0.03).
Conclusions: We have investigated FPGS and TS protein expressions in tumor specimens from the largest series of pemetrexed-treated Caucasian NSCLC patients. Baseline determination of TS and FPGS expression by IHC using the H-score system is associated with clinical outcome from pemetrexed-based therapy in advanced NSCLC. Further prospective validation studies are warranted. |
---|---|
AbstractList | Background: The antifolate pemetrexed targets multiple enzymes involved in pyrimidine and purine synthesis including thymidylate synthase (TS). After entry into cells, pemetrexed is converted to polyglutamated forms by folylpoly-γ-glutamate synthetase (FPGS), a critical step to achieve full target inhibition. We hypothesized that FPGS and TS protein expression may predict outcome following pemetrexed-treatment of patients with advanced NSCLC, like in malignant pleural mesotheliomas (Christoph et al., J Clin Oncol. 2011: 29 suppl.). This is the largest report on pemetrexed-treatment outcome based on TS and FPGS in Caucasian patients with advanced NSCLC.
Methods: Pretreatment tumor samples from 161 patients (pts) with metastatic NSCLC, treated with pemetrexed combined with platinum (74 pts (46%)) or as single agent (82 pts (51%)) or within other combinations (5 pts (3%)), were retrospectively analyzed. FPGS and TS protein expression levels were evaluated by IHC using the H-Scoring system (0–300), which relies on the product of intensity (range 0 to 3) and the percentage of positive tumor cells (0–100%). Radiographic evaluation of response was performed according to RECIST criteria (version 1.1).
Results: Median pretreatment H-scores were 180 for FPGS (range: 0–280) and 205 (range: 120–290) for TS. Using the log-rank test and the median H-score as cut-off, we found a significant association between low TS protein expression and improved progression-free survival (PFS) (median PFS of 5.5 months vs. 3.4 months; hazard ratio [HR] 0.66, 95% CI, 0.45 to 0.96; P=0.03) or prolonged overall survival (median OS of 33.9 months vs. 15.0 months; hazard ratio [HR] 0.52, 95% CI, 0.31 to 0.86; P=0.01). Moreover, high FPGS protein expression was only associated with better PFS (median PFS of 5.5 months vs. 3.4 months; hazard ratio [HR] 0.58, 95% CI, 0.37 to 0.89; P=0.03). Considering exclusively patients suffering from adenocarcinomas (110 pts (68%)), TS was associated with objective response to pemetrexed-based treatment (mean H-score 192 for responders vs. 210 for non-responders, P=0.03).
Conclusions: We have investigated FPGS and TS protein expressions in tumor specimens from the largest series of pemetrexed-treated Caucasian NSCLC patients. Baseline determination of TS and FPGS expression by IHC using the H-score system is associated with clinical outcome from pemetrexed-based therapy in advanced NSCLC. Further prospective validation studies are warranted. |
Author | Welter, Stefan Eberhardt, Wilfried E. Tran, Cindy Schuler, Martin Christoph, Daniel C. Gauler, Thomas C. Asuncion, Bernadette Reyna Hirsch, Fred R. Theegarten, Dirk Peglow, Anja Hassan, Biftu Wynes, Murry W. Loewendick, Heike Wohlschlaeger, Jeremias |
Author_xml | – sequence: 1 givenname: Daniel C. surname: Christoph fullname: Christoph, Daniel C. – sequence: 2 givenname: Heike surname: Loewendick fullname: Loewendick, Heike – sequence: 3 givenname: Anja surname: Peglow fullname: Peglow, Anja – sequence: 4 givenname: Martin surname: Schuler fullname: Schuler, Martin – sequence: 5 givenname: Wilfried E. surname: Eberhardt fullname: Eberhardt, Wilfried E. – sequence: 6 givenname: Fred R. surname: Hirsch fullname: Hirsch, Fred R. – sequence: 7 givenname: Bernadette Reyna surname: Asuncion fullname: Asuncion, Bernadette Reyna – sequence: 8 givenname: Murry W. surname: Wynes fullname: Wynes, Murry W. – sequence: 9 givenname: Thomas C. surname: Gauler fullname: Gauler, Thomas C. – sequence: 10 givenname: Jeremias surname: Wohlschlaeger fullname: Wohlschlaeger, Jeremias – sequence: 11 givenname: Dirk surname: Theegarten fullname: Theegarten, Dirk – sequence: 12 givenname: Stefan surname: Welter fullname: Welter, Stefan – sequence: 13 givenname: Cindy surname: Tran fullname: Tran, Cindy – sequence: 14 givenname: Biftu surname: Hassan fullname: Hassan, Biftu |
BookMark | eNqlUE1PAjEQbQwmgvof5qiHYgvsQrwtGwkmxIN4b0p3gJp-bNoS3R_lf7Rr1Hj3MG8m8-ZN8t6IDJx3SAhwNua8WNxxNl9QNptOxnxSVfXzY7Xd1HRZnpEhL4o5nU7KYpDnn7MLMorxlTE-42w2JB_VLqYgVYJleQ8rbzrTZqAHc0rSyoQQO5eOmGREkK6BdOysbjrzS30RIVeMXum8buBNpyMoo51W0oA_JeUtwj54Cy1aTAHfsaG7rOz_YZBtB9pBdkajlcaAwgzm5A6gpFMY4OZpW2_q2ytyvpcm4vV3vySL1cNLvaYq-BgD7kUbtJWhE5yJPh7R-xa9b_EnHrEsp_-QfgK273a5 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1158/1078-0432.12AACRIASLC-B6 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1557-3265 |
EndPage | B6 |
ExternalDocumentID | 10_1158_1078_0432_12AACRIASLC_B6 |
GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 3O- 476 53G 5GY 5RE 5VS 6J9 AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW AENEX AFHIN AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P QTD RCR RHF RHI RNS SJN TR2 UDS W2D W8F WOQ YKV |
ID | FETCH-crossref_primary_10_1158_1078_0432_12AACRIASLC_B63 |
ISSN | 1078-0432 |
IngestDate | Thu Nov 21 21:03:16 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3_Supplement |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-crossref_primary_10_1158_1078_0432_12AACRIASLC_B63 |
ParticipantIDs | crossref_primary_10_1158_1078_0432_12AACRIASLC_B6 |
PublicationCentury | 2000 |
PublicationDate | 2012-02-01 |
PublicationDateYYYYMMDD | 2012-02-01 |
PublicationDate_xml | – month: 02 year: 2012 text: 2012-02-01 day: 01 |
PublicationDecade | 2010 |
PublicationTitle | Clinical cancer research |
PublicationYear | 2012 |
SSID | ssj0014104 |
Score | 4.1397758 |
Snippet | Background: The antifolate pemetrexed targets multiple enzymes involved in pyrimidine and purine synthesis including thymidylate synthase (TS). After entry... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | B6 |
Title | Abstract B6: Folylpoly-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in non-small cell lung cancer (NSCLC) |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF71ISEuiKd4aw4cQJVDnHhXhptjqFJoOZAi9WbF3g0EHCcKtiD8J_4jM_uy1QZBe1kldjLrZD7t7Mx-M8PYM96PtGEJ-jN0UdBjmAUxH0RBweUg4oVAk0ihgZMPYvwpenfGz3Z29zuspabOe8WvrXklV9EqXkO9UpbsJTTrheIFfI36xRE1jON_6TjJKVBRoIsvyLM_XJabcoUDEdHrKe5FFVUkwC1ejbbKciU3i7nclP6WvkFnCFZNno3uMiaXTY2PrkweykotVL1WP5UMyPxp7iUVJaCoSbWsgu8LOummw4CDsqFsXsLUWnf8maTHqQs7uMoIbg77MVt4yAeofeGDNhf-IO15CtFS_VCVtJ3gx2r-TbXr_OfSVpasvnq7Mym-NDbv0RRP6EY8iDri2SNmke5TVeDIxkWVXbg5LpYD03fi4spOjn-m-6S2hCKzYo9Ex_abNxetCo91gMNO2wsHSZJ-PEomx2kw2lLI-5yB9bRH7XDxOCNJGUnKOpKykdhl-1TPkVpAvDl67w_DolB3wfTzO0Iaj1_-7Zk6u6zOdun0Jrth_RxIDGhvsR1V3WbXTiyT4w777bALI_EatiAXWuQCIhc6yAWHXEDkQotcIOSCQy5Y5AIhF84jFyxyYV6BRy4QcoGQCwaS8Fzj9sVdFh--PU3Hgfu52cpUacn-9WcP77E9lK_uM4iG00LGUypjKqNcDPMZl4UKY6lCIeSr8AELLy3-4RW-84hdb_H-mO3V60Y9wT1vnT_ViPgDhWewkg |
link.rule.ids | 314,780,784,27924,27925 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abstract+B6%3A+Folylpoly-glutamate+synthetase+and+thymidylate+synthase+are+associated+with+clinical+outcome+from+pemetrexed-based+therapy+in+non-small+cell+lung+cancer+%28NSCLC%29&rft.jtitle=Clinical+cancer+research&rft.au=Christoph%2C+Daniel+C.&rft.au=Loewendick%2C+Heike&rft.au=Peglow%2C+Anja&rft.au=Schuler%2C+Martin&rft.date=2012-02-01&rft.issn=1078-0432&rft.eissn=1557-3265&rft.volume=18&rft.issue=3_Supplement&rft.spage=B6&rft.epage=B6&rft_id=info:doi/10.1158%2F1078-0432.12AACRIASLC-B6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1078_0432_12AACRIASLC_B6 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |